Isocel (ALEXIS-ISO-1) / Kiromic - LARVOL DELTA

Comparative outcomes of CAR-T cell therapy with and without autologous stem cell transplant consolidation in diffuse large B-cell lymphoma: A real-world propensity-matched analysis (ASH 2025) - " Using TriNetX, adults (≥18 years) with DLBCL treated with tisacel, lisocel or axicel were identified. ASCT after CAR-T in DLBCL did not improve OS and was associated with increased MDS incidence and higher ICU and hospitalization hazards. Further clinical trials should be designed and studied."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Transplantation

Health care utility and real-world comparison of CAR T-cell therapy versus autologous stem cell transplantation in Relapsed/Refractory diffuse large B-cell lymphoma: A propensity score-matched outcomes analysis (ASH 2025) - " Using the TriNetX Global Collaborative Network, we identified adults (≥18 years) with DLBCL who received either CAR T-cell therapy (axicel or lisocel) or ASCT between February 2021 and August 2024. In this real-world matched analysis, ASCT was associated with improved overall survival compared to CAR T-cell therapy in patients with R/R DLBCL, which could reflect the fact that patients eligible for ASCT were those who achieved remission status and transplant eligible. For healthcare utility perspective, CAR T therapy was linked to lower hospitalization risk, yet associated with increased ICU utilization and infectious complications compared to those of ASCT."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma (ASH 2025) - "Brexucel,lisocel, and the non-covalent BTKi pirto have been approved in this population...Ninety-one pts (86%) received chemo-immunotherapy (CIT), 16 (15%) autologous stem celltransplant, 19 (18%) venetoclax (ven), 29 (27%) chimeric antigen receptor T-cell, 4 (4%) allogeneic stemcell transplant. For cBTKi, 39 (35%) pts received ibrutinib, 56 (50%) pts acalabrutinib, 33 (30%) ptszanubrutinib, and 17 (15%) pts received more than one cBTKi... This is the first RW report on pirto in MCL pts. In this high-risk population, ORR to pirto wascomparable to the BRUIN trial, while PFS was significantly worse, especially in pts w/ no response to cBTKiand w/ a high Ki67. However, prolonged remissions were seen in a subset of pts, suggesting that a bettercharacterization of this population w/ durable benefit from pirto is needed."

Clinical • IO biomarker • Real-world • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • TP53

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study (ASH 2025) - "Among the 1309 patients (pts) enrolled in the study, 93 with R/R PMBCL whoreceived axicel (n=90) or lisocel (n=3) were eligible for this analysis...The type of CPI used,Nivolumab or Pembrolizumab, had no impact on either OS or PFS...Findings ofthis study suggest that the use of CPI is safe and may be beneficial as part of salvage therapy to improvedisease control before infusion or to rescue patients following CAR T-cell failure. Due to the limitednumber of patients experiencing CAR T-cell failure, the optimal salvage strategy in this setting remainsundetermined."

CAR T-Cell Therapy • Checkpoint inhibition • Clinical • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival (ASH 2025) - "Bendamustine was lymphodepletion (LD) for 223 pts (78.5%) (NMSC, n=15[71.4%]; no NMSC, n=208 [79.1%]; ALC-R, n=121 [78.6%]; ALC-NR, n=102 [78.5%]). Of 369 pts screened, 284 were eligible for analysis (22 excluded due to death before CAR-T, 63due to prior NMSC). Of 284 pts, 21 (7.4%) developed NMSC post CAR-T. For 21 pts with NMSC post CAR-T,median age was 65 years (yrs; IQR 61-71); 16 pts (76.2%) were male; 19 (90%) had large B-cell (LBCL), 1(5%) follicular (FL), 1 (5%) mantle cell (MCL) lymphoma; 12 pts (57.1%) received tisacel, 5 (23.8%) axicel, 3(14.3%) lisocel, 1 (4.8%) brexucel."

CAR T-Cell Therapy • IO biomarker • Lymphopenia • B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • CD4

Image-based classification of lymphocyte subsets from routine blood smears reveals distinct immune dynamics after CAR-T infusion (ASH 2025) - "Liso-cel and ide-celdemonstrated sustained near-peak absolute lymphocyte count (ALC) levels through day 30...For example, when comparing Axicel to Lisocel, Lisocel hassignificantly higher ABLs (p<0.01) and lower DCLs (p<0.05)... Peripheral blood smears, a widely available and cost-effective modality, reveal distinct lymphocytemorphologies emerging after CAR-T infusion that can be reproducibly classified using deep learning.These morphologic fingerprints correlate with clinical outcomes and support the further development ofPBS-based immune profiling as a scalable approach for real-time monitoring of CAR-T patients."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Impact of hematopoiesis on collection efficiency for autologous CAR T-cell therapy (DGHO 2025) - "Thereof, commercial CD19-specific and BCMA-specific CAR T-cell products, respectively, (Axicel, Brexucel, Lisocel, Tisacel, Idecel), or CD19-directed CAR T-cells as part of the HD-CAR-1 trial were produced. Statistical analyses included Spearman's correlation, Student's t-test, Welch's t-test, and Mann-Whitney-U test, depending on data distribution. In 181 patients, a sufficient CD3+ T-cell yield was achieved for CAR T-cell manufacturing, while four patients required a second leukapheresis due to not reaching the target yield of ≥10×10⁸ in three patients (Tisacel) and a markedly low CD3+ T-cell yield in one patient possibly due to prior treatment with polatuzumab, bendamustine... For most patients, a sufficient amount of CD3+ T-cells can be collected by a single leukapheresis procedure. However, these findings highlight that leukapheresis for CAR T-cell manufacturing is a critical step and timing is important to reach optimal CAR T-cell therapy outcomes."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • CD8

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma (ASH 2023) - "BT was classified as Polatuzumab (pola) based, intensive chemotherapy, lenalidomide/ Bruton tyrosine kinases inhibitors (len/BTKi), or others...Among all pts, 86 (47%) received Axicel, 49 (27%) Tisacel, 36 (20%) Lisocel and, 11 (6%) Brexucel... Our findings suggest that achieving a response to BT is associated with reduced tumor burden and inflammatory markers pre-LD, reflecting inherent disease biology and treatment-refractoriness. Further studies are required to evaluate which BT strategies may optimize the inflammatory cytokine environment for improved outcomes after CD19 CAR T cell therapy."

CAR T-Cell Therapy • Clinical • Clinical data • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL6

Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ASH 2024) - "Background : Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19, such as Axicabatagene ciloleucel (axicel) and Lisocabtagene maraleucel (lisocel), have shown efficacy with a tolerable safety profile in the treatment of relapsed or refractory diffuse large B-cell lymphoma (RR DLBLC) in clinical trials. Although comparisons for OS cannot be made due to published trial's data maturity, this study provides real-world evidence for pts with RR DLBCL who underwent treatment with either axicel or lisocel. Further maturation of data from clinical trials is needed to better guide treatment for these groups, but comparison data from our analysis looks promising and doesn't show any significant difference between the two products."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Length of Stay (LOS) and Associated Healthcare Resource Use (HCRU) for a First Infusion of Axi-cel or Lisocel in Second Line for Large B-cell Lymphoma in France: Differences Observed From Comprehensive Hospital Databases (ISPOR-EU 2025) - "The majority were monoclonal antibodies, with 48.7% of patients treated with axi-cel (n=167) and 13.5% of patients treated with liso-cel (n=5) receiving tocilizumab or siltuximab. Despite the limited number of patients, a shorter LOS is observed in patients treated with liso-cel compared to those treated with axi-cel, with fewer ICU and extra-DRG drugs, a potential proxy for safety."

Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

A Post-marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-cell Therapy Using the FDA Adverse Event Reporting System (ACR Convergence 2025) - "All individual case safety reports listing any of the CAR-T therapies—tisagenlecleucel (tisacel), axicabtagene ciloleucel (axicel), lisocabtagene maraleucel (lisocel), brexucabtagene autoleucel (brexucel), idecabtagene vicleucel (idecel), and ciltacabtagene autoleucel (ciltacel)—as the suspected drug were included. This post-marketing pharmacovigilance analysis highlights product- and disease-specific patterns of autoimmune AEs following CAR-T therapy. While limited by FAERS reporting bias, these findings support the need for monitoring strategies and emphasize the importance of prospective studies to validate these associations. Integrating pharmacogenomic and immunologic correlates may further elucidate underlying mechanisms."

Adverse events • CAR T-Cell Therapy • IO biomarker • P4 data • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Complement-mediated Rare Disorders • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Indolent Lymphoma • Inflammatory Arthritis • Leukemia • Lupus • Lymphoma • Musculoskeletal Diseases • Myositis • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Rheumatology • Sarcoidosis • Vasculitis • ROR1

"AUC fludarabine and product choice are main predictors of CRS/ICANS after CAR T cell therapy: generation of an improved model" (DGHO 2025) - "Additionally, previous studies only comprised patients treated with tisacel, axi-cel, and a few experimental products. The effects of mEASIX and AUC fludarabine on CRS/ICANS in liso-cel treated or multiple myeloma (MM) patients are unknown... Elevated AUC fludarabine was significantly associated with CRS/ICANS>=°II. In contrast, lisocel and MM were associated with decreased risk. The previously reported association of mEASIX with CRS/ICANS was less pronounced in our models."

CAR T-Cell Therapy • Chronic Kidney Disease • Hematological Malignancies • Multiple Myeloma

A Post-Marketing Analysis of Gastrointestinal Adverse Events Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System (ACG 2025) - "Individual case safety reports listing any CAR-T therapies—Tisagenlecleucel (tisacel), Axicabtagene Ciloleucel (axicel), Lisocabtagene Maraleucel (lisocel), Brexucabtagene Autoleucel (brexucel), Idecabtagene Vicleucel (idecel), and Ciltacabtagene Autoleucel (ciltacel)—as the suspected drug for GI AEs were included. There were 1395 GI AEs with CAR-T reported in FAERS (Table 1). Compared to other CAR-T, Ciltacel was associated with immune effector-cell mediated enterocolitis (IEC-EC) and non-immune colitis; Lisocel with GI ulceration, necrosis, and cholestasis; Idecel with functional/motility disorders; and Axicel and Tisacel with GI bleed. Tisacel was also associated with abnormal liver function tests, pancreatitis, and functional/motility disorders.Distinct patterns were observed based on primary cancer."

Adverse events • CAR T-Cell Therapy • P4 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Cholestasis • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Immunology • Large B Cell Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pancreatitis • Primary Mediastinal Large B-Cell Lymphoma

Best of Cell Therapy for Lymphoma: What We Learned in 2024 and 2025 (SOHO 2025) - P1/2, P2 | "Autologous CAR-T Therapy CD19 CAR-T New Regulatory Approvals In March 2024, the United States Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (lisocel) for relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) after Bruton tyrosine kinase inhibitors (BTKis) and B-cell lymphoma 2 (BCL2) inhibitors, making it the first CAR-T approval in this disease...Long-Term Follow-up of Pivotal CD19 CAR-T Trials TRIAL (PRODUCT) LYMPHOMA SUBTYPE MEDIAN FU (MONTHS) ORR (%) CR (%) MEDIAN PFS (MONTHS) PFS (%) OS (%) NOTABLE SAFETY FINDINGS 64.6 90 75 (79% in FL cohort, 65% in MZL cohort) 62.2 53 (5 yr) 69 (5 yr) No new late signals ZUMA-5 (AXICEL) FL/MZL ( ≥ 3L) ELARA (TISA-CEL) FL ( ≥ 3L) 53 – * 69.1 53.3 50.2 (4 yr) 79.3 (4 yr) No new late signals; 6.2% secondary primary malignancies TRANSCEND FL (LISO-CEL) FL (2L+ high-risk/3L+) 29.5 – 30 95.7 – 97.1 94.2 – 95.7 NR 72.5 – 82.6 (2 yr) 88.2 –..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Oncology • Peripheral T-cell Lymphoma • Small Lymphocytic Lymphoma • T Cell Non-Hodgkin Lymphoma • CD22 • CD5 • IL15 • TNFRSF8

Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience (SOHO 2025) - "Background: CAR T-cell therapies show remarkable efficacy in B-cell non-Hodgkin lymphoma. In lisocel pivotal trial and SOC settings, most CRS/ICANS occurred ≤2 weeks after infusion and were not severe. For the few patients with CRS/ICANS onset >D15, most events were low grade and resolved. Funding: Bristol Myers Squibb."

Clinical • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study (SOHO 2025) - P2 | "In patients with R/R MZL, lisocel demonstrated deep and durable responses with high 24-month survival rates. With a manageable safety profile, liso-cel is a potential treatment option for patients with R/R MZL. Funding: Celgene, a Bristol-Myers Squibb Company."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24) (SOHO 2025) - "Background: We report subgroup analyses by number of prior LOTs, POD24 status, and prior bendamustine exposure in lisocel-treated patients from the FL cohort of TRANSCEND FL. Data support sustained clinical benefit and manageable safety of liso-cel in patients with R/R FL, regardless of POD24 and prior bendamustine, trending towards better outcomes in earlier LOTs. Funding: Celgene, a Bristol-Myers Squibb Company."

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

AUC FLUDARABINE AND PRODUCT CHOICE ARE MAIN PREDICTORS OF CRS/ICANS AFTER CAR T CELL THERAPY: GENERATION OF AN IMPROVED MODEL (ICML 2025) - "Additionally, previous studies only comprised patients treated with tisacel, axi-cel, and a few experimental products. The effects of mEASIX and AUC fludarabine on CRS/ICANS in liso-cel treated or multiple myeloma (MM) patients are unknown... Elevated AUC fludarabine was significantly associated with CRS/ICANS ≥°II. In contrast, lisocel and MM were associated with decreased risk. The previously reported association of mEASIX with CRS/ICANS was less pronounced in our models."

CAR T-Cell Therapy • Lymphoma • Multiple Myeloma

AUC FLUDARABINE AND PRODUCT CHOICE ARE MAIN PREDICTORS OF CRS/ICANS AFTER CAR T CELL THERAPY: GENERATION OF AN IMPROVED MODEL (EHA 2025) - "Additionally, previous studies only comprised patients treated with tisacel or axi-cel, and a few experimental products...After exclusion of gender, patient weight and brexu-cel as predictors, mEASIX, AUC fludarabine, age, liso-cel, and MM were included as predictors for ICANS>=°II... Elevated AUC fludarabine was significantly associated with severe CRS/ICANS. In contrast, lisocel and MM were associated with decreased risk. The previously reported association of mEASIX with CRS/ICANS was less pronounced in our models."

CAR T-Cell Therapy • Chronic Kidney Disease • Hematological Malignancies • Multiple Myeloma • Oncology

PERSISTING THROMBOCYTOPENIA AFTER CD19-DIRECTED CAR-T CELL THERAPY IS A PREDICTOR OF WORSE SURVIVAL IN RELAPSED / REFRACTORY LBCL PATIENTS (EHA 2025) - "The administered CAR-T cell products were as following: Axicel (n=79; 87%), Tisacel (n=11; 12%) and Lisocel (n=1; 1%).Cytopenias ≥ grade 3 were a frequent event in follow-up in our cohort with a maximum at d+30 (Granulocytopenia 37%, Anemia 8%, Thrombocytopenia 48%). Cytopenias are a frequent event in post-CAR-T phase in r/r LBCL. Of all scenarios, persisting Thrombocytopenia CTC ≥ 2 at d+90 after CAR-T cell therapy was a strong predictor for worse survival. Patients with thrombocytopenia grade ≥ 2 should be monitored carefully in post-CAR-T follow-up."

CAR T-Cell Therapy • Clinical • Agranulocytosis • Anemia • B Cell Lymphoma • Granulocytopenia • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia

Real world and Appalachian comparison of axicabtagene ciloleucel and lisocabtagene maraleucel in relapsed/refractory diffuse large B-cell lymphoma. (ASCO 2025) - "Funded by No funding sources reported Background: Chimeric antigen receptor T-cell therapies targeting CD19, like Axicabatagene ciloleucel (axicel) and Lisocabtagene maraleucel (lisocel), shown efficacy with a tolerable safety treating relapsed/refractory diffuse large B-cell lymphoma (RR DLBCL) in clinical trials. TNX and WVU is comparable to trial data for more all grade ICANS noted in axicel compared to lisocel. More CRS noted with WVU population which is comparable to clinical trial data. Further clinical trials comparing axicel and lisocel is needed to better guide treatment for these pts."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Theoretical Analysis of Power-Law Stress Relaxation and Calcium-Dependent Passive Mechanics in Cardiac Muscle. (PubMed, bioRxiv) - "By providing a unified basis for the observed viscoelastic and preconditioning effects, calcium dependency, and power-law stress relaxation phenomena, this study offers a novel theoretical basis for understanding and simulating the role of titin in striated muscle mechanics. 1Passive stress relaxation of cardiac muscle follows a power-law decay, a phenomenon that is explained using a theoretical model of dynamic unfolding of globular domains along polymer chain.The theoretical model simulates the behavior of titin, a giant sarcomere protein linking myosin thick filaments to the Z disk and providing passive restoring force during muscle stretch.The theoretical model is able to account the observed effects of calcium on the effective viscoelastic passive mechanics of cardiac muscle.This model provides a theoretical basis for understanding passive visocelastic properties and titin's role in striated muscle mechanics."

Journal • TTN

Low Symmetry Face-Capped Fe(II) Tetrahedra Through Anisotropic Ligand Extension. (PubMed, Angew Chem Int Ed Engl) - "The use of 'isoceles' ligands (two arms the same, one different) gives tetragonal disphenoid structures, while a 'scalene' ligand (all three arms different) gives a rhombic disphenoid structure...More distorted cages were more prone to loss of structural integrity upon introduction of highly coordinating dimethyl sulfoxide solvent into the cage in acetonitrile solution. As well, increasing distortion was shown to increase the ease of oxidation from Fe(II) to Fe(III) within the cages."

Journal

Real World Outcomes of CAR T-Cell Therapy for B-Cell Lymphoma in Adults Age ≥ 65: A Referral Center Experience (TCT-ASTCT-CIBMTR 2025) - "CAR T products included: 36 Axicel, 12 Brexucel, 10 Lisocel, and 3 Tisacel. Among the 61 patients, 49 had DLBCL/HGBL and 12 had MCL; the median age was 72 years old (range 65-84) and 38 patients were male. Median prior lines of therapy were 2 (range 1-11) including 9 prior autologous transplants. The pre-CAR T Karnofsky performance score (KPS) was 90 - 100 in 26 patients and ≤ 80 for 35 patients."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases

State of knowledge of the ladybird beetle (Coleoptera, Coccinellidae) fauna of Armenia and other Transcaucasian countries, including two new country records. (PubMed, Zookeys) - "Two of them, Anatisocellata (Linnaeus, 1758) and Tytthaspissedecimpunctata (Linnaeus, 1761), have not been reported in the literature but were present in our field samples, so they can be considered species new to Armenia, and signify new country records...The recognized Coccinellidae fauna of Armenia is slightly poorer than the faunas of other Transcaucasian countries (Azerbaijan and Georgia): there are 92 species currently known to occur in Azerbaijan and 90 species in Georgia. Interestingly, the Armenian fauna contains more Caucasian endemics (10 species) and fewer non-natives (1 species) than the faunas of Azerbaijan (4 endemics and 2 non-natives) and Georgia (6 endemics and 6 non-natives)."

Journal